Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International journal of pharmaceutics

• Publication date

  2007-04-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijpharm.2006.10.039PMID 17137735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006cited by this paper
• High throughput microsomal stability assay for insoluble compounds.

  2006cited by this paper
• CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions

  2005cited by this paper
• Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.

  2005cited by this paper
• High throughput P450 inhibition screens in early drug discovery.

  2005cited by this paper
• In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: Qualitative relationships, quantitative predictions, and the rank‐order approach

  2005cited by this paper
• Applications of high-throughput ADME in drug discovery.

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Metabolic screening in vitro: metabolic stability, CYP inhibition and induction.

  2004cited by this paper
• Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries.

  2004cited by this paper
• Experimental design on single-time-point high-throughput microsomal stability assay.

  2004cited by this paper
• Automation and robotics in ADME screening.

  2004cited by this paper
• Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Profiling drug-like properties in discovery research.

  2003cited by this paper
• Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

  2003cited by this paper
• High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.

  2003cited by this paper
• Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.

  2003cited by this paper
• Pharmaceutical profiling in drug discovery.

  2003cited by this paper
• In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

  2003cited by this paper
• Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products.

  2002cited by this paper
• Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

  2002cited by this paper
• Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50

  2002cited by this paper
• Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry.

  2002cited by this paper
• Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.

  2001cited by this paper
• Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.

  2001cited by this paper
• Screening of drug candidates for their drug--drug interaction potential.

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.

  2001cited by this paper
• Screening for human ADME/Tox drug properties in drug discovery.

  2001cited by this paper
• A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.

  2001cited by this paper
• Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

  2001cited by this paper
• Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus

  2001cited by this paper
• Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

  2000cited by this paper
• Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

  2000cited by this paper
• High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment.

  2000cited by this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999cited by this paper
• Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues

  1999cited by this paper
• Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.

  1999cited by this paper
• Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

  1999cited by this paper
• Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

  1999cited by this paper
• Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes

  1999cited by this paper
• Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

  1997cited by this paper

• The effects of polyethylene microplastics on the growth, reproduction, metabolic enzymes, and metabolomics of earthworms Eisenia fetida.

  2023cites this paper
• Inhibition of Cytochrome P450s by Strobilanthes crispus Sub-Fraction (F3): Implication for Herb–Drug Interaction

  2022cites this paper
• Biomedical Applications of Polyurethane Hydrogels, Polyurethane Aerogels and Polyurethane-Graphene Nanocomposite Materials.

  2022cites this paper
• Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling.

  2020cites this paper
• In vitro characterization and in vitro to in vivo predictions of drug-drug interactions

  2020cites this paper
• Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes

  2019cites this paper
• In Vitro and In Vivo Methods to Assess Pharmacokinetic Drug-Drug Interactions in Drug Discovery and Development.

  2019cites this paper
• Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry

  2019cites this paper
• Method for Determining CYP2C9 Activity in Earthworms and its Responses to Benzo[a]pyrene or Pyrene in Soil

  2019cites this paper
• Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.

  2018cites this paper
• Evaluation of hepatic activity of immunomodulatory compounds and GSK3 inhibitors

  2017cites this paper
• Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.

  2016cites this paper
• CYP Inhibition Methods

  2016cites this paper
• Substrate Hunting for the Myxobacterial CYP260A1 Revealed New 1α‐Hydroxylated Products from C‐19 Steroids

  2016cites this paper
• In vitro–in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure

  2015cites this paper
• Medicinal Chemistry and Lead Optimization of Marine Natural Products

  2015cites this paper
• Artigo A Comparative Evaluation of Acetylcholinesterase Inhibition by AChE-ICER and in vitro Ell a ’ s Modified Method of Si plified Analogs 3O-Acetyl-N-Benzyl-Piperidine of Donepezil

  2015cites this paper
• Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain.

  2015cites this paper
• Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.

  2015cites this paper
• A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies.

  2014cites this paper
• Metabolism-oriented Lead Optimization of Propargyl-linked DHFR Inhibitors

  2014cites this paper
• Phenotyping of CYP450 in human liver microsomes using the cocktail approach

  2014cites this paper
• Functional effects of cytochrome P450 variants on drug metabolism and adverse drug reactions: developing and extending high throughput P450 protein technology platforms

  2014cites this paper
• A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.

  2014cites this paper
• Evaluation of the effect of compound aqueous solubility in cytochrome P450 inhibition assays

  2013cites this paper
• Modern methods of cytochrome P450 analysis

  2013cites this paper
• Combining in silico protein stability calculations with structure-function relationships to explore the effect of polymorphic variation on cytochrome P450 drug metabolism.

  2013cites this paper
• High-throughput mass spectrometric cytochrome P450 inhibition screening.

  2013cites this paper
• High-throughput fluorescence assay of cytochrome P450 3A4.

  2013cites this paper
• Sample reduction strategies in discovery bioanalysis.

  2013cites this paper
• Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity.

  2013cites this paper
• Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards.

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012cites this paper
• [Current methods of cytochrome p450 analysis].

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012cites this paper
• 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 2): action in other targets and antitargets.

  2012cites this paper
• In Vitro ADME Profiling Using High-Throughput RapidFire Mass Spectrometry

  2012cites this paper
• Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).

  2012cites this paper
• Optimal ADME Properties for Clinical Candidate and Investigational New Drug (IND) Package

  2012cites this paper
• Fast and Reliable CYP Inhibition Assays

  2012cites this paper
• In Vitro Liver Systems to Study Induction/Inhibition: Prediction of In Vivo Metabolism and Drug–Drug Interactions

  2012cites this paper
• [Mass-spectrometric measurements of P450 isoform specific content and corresponding enzyme activities].

  2011cites this paper
• Mass spectrometric determination of the quantity and enzyme activity of cytochromes P450

  2011cites this paper
• The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise?

  2011cites this paper
• Bioanalytical Support for Both In Vitro and In Vivo Assays Across Drug Discovery and Drug Development

  2011cites this paper
• Use of Triple Quadrupole–Linear Ion Trap Mass Spectrometry as a Single LC–MS Platform in Drug Metabolism and Pharmacokinetics Studies

  2011cites this paper
• Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.

  2011cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• B.13 In Vitro/In Vivo Correlation for Drug-Drug Interactions

  2011cites this paper
• Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.

  2010cites this paper
• Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors.

  2010cites this paper
• Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles.

  2010cites this paper
• A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of Pooled and Cocktail cytochrome P450 assays.

  2010cites this paper
• Application of cytochrome P450 drug interaction screening in drug discovery.

  2010cites this paper
• ADMET In Vitro Profiling: Utility and Applications in Lead Discovery

  2010cites this paper
• A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s.

  2010cites this paper
• Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).

  2010cites this paper
• Multiple surface plasmon biosensor assay as new tool for probing metabolic evaluation of CYP2D6

  2009cites this paper
• Drug–Drug Interactions: Screening for Liability and Assessment of Risk

  2009cites this paper
• The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.

  2009cites this paper
• Development of a Fluorescence-Based, Ultra High-Throughput Screening Platform for Nanoliter-Scale Cytochrome P450 Microarrays

  2009influential citation
• Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).

  2009cites this paper
• Advances in the integration of drug metabolism into the lead optimization paradigm.

  2009cites this paper
• Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition.

  2009cites this paper
• Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.

  2009cites this paper
• Cytochrome P450 metabolism and inhibition: analysis for drug discovery.

  2009cites this paper
• ADME optimization and toxicity assessment in early- and late-phase drug discovery.

  2009cites this paper
• Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values

  2009influential citation
• An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.

  2008cites this paper
• Development of Fluorescence-Based High-Throughput Assays for Evaluation of ADME-Tox Properties in Drug Discovery

  2008cites this paper
• In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions

  2008influential citation
• ADME Properties of Drugs

  2008cites this paper
• Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization

  2008cites this paper
• Chapter 32 – CYP Inhibition Methods

  2008cites this paper
• In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: thin layer chromatography versus microplate methods.

  2008cites this paper
• Multifunctional hits against Alzheimer's and Parkinson's diseases : screening for acetylcholinesterase and protein aggregation inhibitors

  2008cites this paper
• Current applications of liquid chromatography/mass spectrometry in pharmaceutical discovery after a decade of innovation.

  2008cites this paper
• An update on metabolism studies using human hepatocytes in primary culture

  2008cites this paper
• N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2).

  2008cites this paper
• An update on metabolism studies using human hepatocytes in primary culture.

  2008cites this paper